We’re proud to move forward every day!

  • 14th August, 2020

    Eight Patients are now Enrolled in the ImmuoSABR Clinical Trial

    Our trial is steadily progressing and we now have eight patients in three centres enrolled in the ImmunoSABR trial .

  • 3rd February, 2020

    First Patients Enrolled in ImmuoSABR Clinical Trial

    Great news the first patients have been enrolled in the ImmunoSABRclinical Trial at NKI and AZM

  • 2nd June, 2019

    METC Approval

    METC approval received for the centres in Maastricht, Amsterdam and Nijmegen

  • 22nd February, 2019

    Annual ImmunoSABR Meeting 2019

    Partners Meeting held in Amsterdam reporting on the progress of the project.

  • 1st December, 2018

    New ImmunoSABR Website Launched

    A new website has been designed to provide an overview of the ImmunoSABR project, its progress and information to the general public, patients and potential patients

  • 1st October, 2018

    Presentation - Brussels & Roma

    Professor Philippe Lambin - Immunocytokines and Radiation at the Institut Bordet, Brussels. Unconventional immunotherapy and Radiation given in Roma at the yearly national course of radiation Oncology

  • 1st September, 2018

    Presentation - Paris

    Professor Philippe Lambin given in Paris at the Immunorad meeting immunocytokines and radiation

  • 1st August, 2018

    Presentation - New York

    Professor Philippe Lambin given in New York MSKCC on Immunocytokines and radiation

  • 1st July, 2018

    Presentation - Liverpool UK

    Professor Philippe Lambin on Immunocytokines and Radiation given in Liverpool UK at UK Radiological Congress and Radiation and Oncology Congress (UKRCO)

  • 1st June, 2018

    Amendment EU, Periodic report, (Ready for) Submission

    Protocol final, ICF and patient info final, Other documents for submission final, EU amendment Part A and B final, EU Technical Report part B final, CTA final and signed, Finalizing deliverables

  • 1st June, 2018

    New Data

    New data with three tumour models form the M-lab of precision medicine showing that immunocytokines, used in ImmunoSABR, worked better than checkpoint inhibitors with radiation.

  • 1st May, 2018

    New Participant

    Presentation by Professor Philippe Lambin in Antwerpen on ImmunoSABR led to them becoming a participant

  • 1st April, 2018

    Presentation - Barcelona

    Presentation by Professor Philippe Lambin (The M-Lab of Precision medicine) given at the ESTRO meeting in Barcelona on novel immunotherapy radiotherapy strategies Presentation by Damienne Marcus (The M-Lab of Precision medicine) given at the ESTRO meeting in Barcelona in on immunocytokines and radiation

  • 1st March, 2018

    Presentation - Utrecht

    Presentation by Professor Philippe Lambin given at the NVRO-NVRB meeting in Utrecht in on immunocytokines and radiation

  • 1st February, 2018

    Presentation - Lille

    Presentation by Professor Philippe Lambin given in Lille centre Oscar lambret a participant to the trial.

  • 1st January, 2018


    Tender (Negometrix), Submissions, Safety reporting, Risk analysis, Local monitors (visits), Training partners, Trial master file

  • 1st March, 2017

    Kick Off Meeting - Presentation

    First presentation was given by Professor Philippe Lambin , Brussels Kick off meeting introducing ImmunoSABR for a broad audience.

  • 1st January, 2017

    H2020 Grant

    H20H20 grant - We received an H2020 grant from the European Union that helps us to cover the financial part for this study. We are working with a number of hospitals and centres throughout the European Union and aim to encompass patients within the whole of the EU

Stay informed?

If you want to stay informed about ImmunoSABR project, please subscribe to our newsletter.